DPP-4 Therapy Center - Diabetes In Control

Liraglutide and Sitagliptin Useful for Nonalcoholic Fatty Liver Disease in T2DM

4 weeks ago Type 2 Diabetes, DPP-4 Therapy Center, GLP-1 Agonist Therapy Center

A recent study reveals Liraglutide and Sitagliptin reduce intrahepatic lipid in patients with T2DM and IHL.

The CARMELINA Trial: Linagliptin’s Cardiovascular Effects for Type 2 Diabetes with High Cardiorenal Risk — ADA 2019

Jul 2, 2019 Type 2 Diabetes, Cardiology, Nephrology, DPP-4 Therapy Center

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes.

Patients With T2D, Mild Renal Impairment Can Benefit From A DPP-4 Inhibitor

Aug 25, 2018 Type 2 Diabetes, Nephrology, Articles, DPP-4 Therapy Center

Sitagliptin showed greater glycemic efficacy over dapagliflozin when added onto existing therapy.

Dipeptidyl Peptidase-4 Inhibitors and Incidence of Inflammatory Bowel Disease

May 5, 2018 Articles, DPP-4 Therapy Center

Prolonged use of medication increases risk of bowel condition, but exact cause yet to be determined.

Understanding The Gap Between Efficacy In Randomized Trials And Effectiveness In Real-World Use Of GLP-1RA and DPP-4 Therapies

Jan 13, 2018 Type 2 Diabetes, Articles, DPP-4 Therapy Center

Patients are not seeing the expected results because of medication adherence.

Greater HbA1c Reduction with DPP4 Inhibitor, AGI Combination

Dec 16, 2017 Type 2 Diabetes, Articles, DPP-4 Therapy Center

Additive glucose-lowering effect of a dipeptidyl peptidase-4 (DPP4) inhibitor and an alpha-glucosidase inhibitor (AGI) might be beneficial in patients with T2DM.

Heart Failure Warning Added to the DPP-4 Inhibitor Class of Drugs

Oct 7, 2017 Articles, Blood Glucose Control, DPP-4 Therapy Center

Increased cardio risk of Saxagliptin found during trial prompts FDA decision.

DPP-4 Inhibitor Safe & Effective for Type 2’s With CVD

Jan 19, 2017 DPP-4 Therapy Center

The DPP-IV inhibitor sitagliptin was safe and effective over 3 years for adults aged at least 75 years who had well-controlled type 2 diabetes and cardiovascular disease, findings from an analysis of TECOS study data show.